Cryptogenic organizing pneumonia medical therapy

Revision as of 15:25, 27 February 2018 by Manpreet Kaur (talk | contribs)
Jump to navigation Jump to search

Cryptogenic Organizing Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cryptogenic organizing pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Electrocardiogram

Ultrasonography/Echocardiography

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cryptogenic organizing pneumonia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cryptogenic organizing pneumonia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cryptogenic organizing pneumonia medical therapy

CDC on Cryptogenic organizing pneumonia medical therapy

Cryptogenic organizing pneumonia medical therapy in the news

Blogs on Cryptogenic organizing pneumonia medical therapy

Directions to Hospitals Treating Cryptogenic organizing pneumonitis

Risk calculators and risk factors for Cryptogenic organizing pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Manpreet Kaur, MD [2]

Overview

Medical Therapy

About two-thirds of patients recover with corticosteroid therapy. Prednisolone is often administered in Europe and prednisone in the USA. These two compounds differ by only one functional group and have the same clinical effect. The steroid is initially administered at high doses, typically 50 mg per day tapering down to zero over a 6 month to one year period. If the steroid treatment is halted too quickly the disease may return.

References